PVI
FATE icon

Pura Vida Investments’s Fate Therapeutics FATE Stock Holding History

Pura Vida Investments’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-59,600
Closed -$582K – 104
2018
Q1 		$582K Buy
+59,600
New +$571K 0.34% 57

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Pura Vida Investments's FATE Position: Q2 2018 in Review

Pura Vida Investments sold out of Fate Therapeutics (FATE) in Q2 2018, closing a stake of 59,600 shares — an estimated $582K sold.

Pura Vida Investments first reported a position in FATE in Q1 2018 and held it in 1 quarter. The position peaked at $582K in Q1 2018. 103 funds tracked by Wall St. Rank hold FATE as of Q2 2018.

  • Pura Vida Investments reported no remaining Fate Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Pura Vida Investments sold 59,600 Fate Therapeutics shares in Q2 2018, an estimated $582K.
  • Pura Vida Investments first reported a position in Fate Therapeutics in Q1 2018 and held it in 1 quarter.
  • Pura Vida Investments's Fate Therapeutics position peaked at $582K in Q1 2018.
  • 103 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2018.

Based on Pura Vida Investments's 13F filing for Q2 2018, filed 14 Aug 2018.